Source: Annual Congress 2011 - Asthma management and response
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
V. Norris, J. Bentley, S. Kent, D. Singh, M. Boyce, B. Leaker (Stevenage, Manchester, London, United Kingdom). The effect of GSK2190915, a 5-lipoxygenase activating protein inhibitor, on the early asthmatic response to inhaled allergen. Eur Respir J 2011; 38: Suppl. 55, 3966

Member's Comments

No comment yet.

Related content which might interest you: The effect of GSK2190915, a 5-lipoxygenase activating protein inhibitor, on the allergen induced asthmatic response Source: Annual Congress 2011 - New treatments for airway disease Year: 2011 Quantitative assessment of cysteinyl leukotrienes in human sputum during the allergen-induced asthmatic response and the effect of GSK2190915, a 5-lipoxygenase activating protein (FLAP) inhibitor Source: Annual Congress 2011 - Diagnosis and treatment of inflammatory respiratory diseases Year: 2011 The inhaled PDE4 inhibitor GSK256066 significantly inhibits airway responses following allergen challenge in asthmatics Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008 Dose-dependent inhibitory effect of Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, on allergen-induced early and late asthmatic reaction Source: Eur Respir J 2002; 20: Suppl. 38, 110s Year: 2002 Effect of a novel inhaled glucocorticoid, ciclesonide, on an allergen-induced asthmatic response in rats and its prolonged anti-inflammatory activity in vitro Source: Eur Respir J 2002; 20: Suppl. 38, 91s Year: 2002 Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459 Source: Eur Respir J 2013; 41: 46-52 Year: 2013 Effect of combined leukotriene, histamine antagonism on the early response to inhaled allergen Source: Eur Respir J 2005; 26: Suppl. 49, 583s Year: 2005 The inhaled PDE4 inhibitor UK-500,001 does not significantly inhibit airway responses to allergen and histamine Source: Annual Congress 2007 - New drugs for asthma Year: 2007 Montelukast as add-on therapy to β-agonists and late airway response Source: Eur Respir J 2007; 30: 56-61 Year: 2007 The effect of single dose montelukast and desloratadine, alone and in combination, on the allergen induced late airway response in atopic asthma Source: Annual Congress 2008 - New mechanisms in the pathogenesis of asthma and its response to treatment Year: 2008 Inhibition of the inhaled allergen challenge response by the CRTH2 antagonist OC000459 in patients with asthma Source: Annual Congress 2010 - Novel anti-inflammatory agents for airway disease Year: 2010 Inhaled synthetic surfactant abolishes the early allergen-induced response in asthma Source: Eur Respir J 2003; 21: 1046-1049 Year: 2003 Effects of 5-lipoxygenase inhibitor on airway responses to inhaled organic dust in healthy subjects Source: Eur Respir J 2002; 20: Suppl. 38, 307s Year: 2002 Inhaled IL-4/IL-13 antagonist decreases response to antigen challenge in atopic asthmatic subjects Source: Eur Respir J 2007; 30: Suppl. 51, 490s Year: 2007 The potent and lung-selective inhaled pan JAK inhibitor TD-8236 limits airway inflammation without affecting systemic immunity in mice Source: International Congress 2019 – Novel targets and mechanisms in asthma Year: 2019 Reduced late asthmatic response by repeated low-dose allergen exposure Source: Eur Respir J 2001; 17: 872-880 Year: 2001 The effect of a leukotriene antagonist, pranlukast, on allergen-induced airway responses and circulating dendritic cells in subjects with atopic asthma Source: Eur Respir J 2003; 22: Suppl. 45, 414s Year: 2003 Combined treatment with fluticasone plus salmeterol protects against allergen induced asthmatic responses and subsequent increase in sputum eosinophils Source: Eur Respir J 2002; 20: Suppl. 38, 189s Year: 2002 Assessment of in vivo 5-lipoxygenase (5-LO) activity in nonatopic and atopic subjects with or without asthma: effects of treatment with the 5-LO inhibitor zileuton Source: Eur Respir J 2003; 22: Suppl. 45, 101s Year: 2003 PBF-680, an oral A1 adenosine receptor antagonist, inhibits the late allergic response (LAR) in mild-to-moderate atopic asthmatics: a Phase-IIa trial Source: Virtual Congress 2020 – Cutting edge science: novel molecules and mechanisms of airway diseases Year: 2020